385 related articles for article (PubMed ID: 20594363)
1. Bench-to-bedside review: The role of beta-lactamases in antibiotic-resistant Gram-negative infections.
Bush K
Crit Care; 2010; 14(3):224. PubMed ID: 20594363
[TBL] [Abstract][Full Text] [Related]
2. Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens.
Pfeifer Y; Cullik A; Witte W
Int J Med Microbiol; 2010 Aug; 300(6):371-9. PubMed ID: 20537585
[TBL] [Abstract][Full Text] [Related]
3. [Mechanisms of resistance in Enterobacteriaceae towards beta-lactamase antibiotics].
Susić E
Acta Med Croatica; 2004; 58(4):307-12. PubMed ID: 15700687
[TBL] [Abstract][Full Text] [Related]
4. [MULTIRESISTANT BACTERIA].
Bedenić B; Sardelić S; Ladavac M
Acta Med Croatica; 2015 Sep; 69(3):211-6. PubMed ID: 29077379
[TBL] [Abstract][Full Text] [Related]
5. [Broad-spectrum beta-lactamases in Gram-negative bacteria].
Sundsfjord A; Simonsen GS; Haldorsen B; Lundblad EW; Samuelsen O
Tidsskr Nor Laegeforen; 2008 Dec; 128(23):2741-5. PubMed ID: 19079424
[TBL] [Abstract][Full Text] [Related]
6. Proliferation and significance of clinically relevant β-lactamases.
Bush K
Ann N Y Acad Sci; 2013 Jan; 1277():84-90. PubMed ID: 23346859
[TBL] [Abstract][Full Text] [Related]
7. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
8. Current challenges in antimicrobial chemotherapy: the impact of extended-spectrum beta-lactamases and metallo-beta-lactamases on the treatment of resistant Gram-negative pathogens.
Helfand MS; Bonomo RA
Curr Opin Pharmacol; 2005 Oct; 5(5):452-8. PubMed ID: 16084766
[TBL] [Abstract][Full Text] [Related]
9. Gram-negative bacilli resistant to third-generation cephalosporins: beta-lactamase characterization and susceptibility to Sch 34343.
Medeiros AA; Hare R; Papa E; Adam C; Miller GH
J Antimicrob Chemother; 1985 Jun; 15 Suppl C():119-32. PubMed ID: 3875602
[TBL] [Abstract][Full Text] [Related]
10. beta-Lactamases of increasing clinical importance.
Bush K
Curr Pharm Des; 1999 Nov; 5(11):839-45. PubMed ID: 10539991
[TBL] [Abstract][Full Text] [Related]
11. Carbapenemases: molecular diversity and clinical consequences.
Poirel L; Pitout JD; Nordmann P
Future Microbiol; 2007 Oct; 2(5):501-12. PubMed ID: 17927473
[TBL] [Abstract][Full Text] [Related]
12. Structural and Functional Aspects of Class A Carbapenemases.
Naas T; Dortet L; Iorga BI
Curr Drug Targets; 2016; 17(9):1006-28. PubMed ID: 26960341
[TBL] [Abstract][Full Text] [Related]
13. Activity of OP0595/β-lactam combinations against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing β-lactamases.
Livermore DM; Mushtaq S; Warner M; Woodford N
J Antimicrob Chemother; 2015 Nov; 70(11):3032-41. PubMed ID: 26311835
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial susceptibility and beta-lactamase production of selected gram-negative bacilli from two Croatian hospitals: MYSTIC study results.
Bedenic B; Goic-Barisic I; Budimir A; Tonkic M; Mihajkevic LJ; Novak A; Sviben M; Plecko V; Punda-Polic V; Kalenic S
J Chemother; 2010 Jun; 22(3):147-52. PubMed ID: 20566417
[TBL] [Abstract][Full Text] [Related]
15. Epidemiological expansion, structural studies, and clinical challenges of new β-lactamases from gram-negative bacteria.
Bush K; Fisher JF
Annu Rev Microbiol; 2011; 65():455-78. PubMed ID: 21740228
[TBL] [Abstract][Full Text] [Related]
16. Gram-negative bacteria as causative agents of ventilator-associated pneumonia and their respective resistance mechanisms.
Bandić-Pavlović D; Zah-Bogović T; Žižek M; Bielen L; Bratić V; Hrabač P; Slačanac D; Mihaljević S; Bedenić B
J Chemother; 2020 Nov; 32(7):344-358. PubMed ID: 32729399
[TBL] [Abstract][Full Text] [Related]
17. [Beta-lactamases of Gram negative bacteria: never-ending clockwork!].
Philippon A; Arlet G
Ann Biol Clin (Paris); 2006; 64(1):37-51. PubMed ID: 16420989
[TBL] [Abstract][Full Text] [Related]
18. New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship.
Jean SS; Gould IM; Lee WS; Hsueh PR;
Drugs; 2019 May; 79(7):705-714. PubMed ID: 30972660
[TBL] [Abstract][Full Text] [Related]
19. β-lactamase-mediated resistance: a biochemical, epidemiological and genetic overview.
Gutkind GO; Di Conza J; Power P; Radice M
Curr Pharm Des; 2013; 19(2):164-208. PubMed ID: 22894615
[TBL] [Abstract][Full Text] [Related]
20. [Beta-lactamases and their role in resistance. PART 2: beta-lactamases in 21st century].
Bedenić B
Lijec Vjesn; 2005; 127(1-2):12-21. PubMed ID: 16145868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
